Observational study of the relative efficacy of insulin-glucose treatment for hyperkalaemia in patients with liver cirrhosis.

OBJECTIVES: To determine if liver cirrhosis is associated with reduced efficacy of insulin-glucose treatment in moderate to severe hyperkalaemia. DESIGN: Retrospective, cohort study. SETTING: Two secondary and one tertiary care hospital at a large metropolitan healthcare network in Melbourne, Australia. PARTICIPANTS: This study included 463 adults with a mean age of 68.7±15.8 years, comprising 79 patients with cirrhosis and 384 without cirrhosis as controls, who received standard insulin-glucose treatment for a serum potassium ≥6.0 mmol/L from October 2016 to March 2020. Patients were excluded if they received an insulin infusion, or if there was inadequate follow-up data for at least 6 hours after IDT due to death, lost to follow-up or inadequate biochemistry monitoring. The mean Model for End-stage Liver Disease score in patients with cirrhosis was 22.2±7.5, and the distribution of the Child-Pugh score for cirrhosis was: class A (24%), class B (46%), class C (30%). OUTCOME MEASURES: The primary outcome was the degree of potassium lowering and the secondary outcome was the proportion of patients who achieved normokalaemia, within 6 hours of treatment. RESULTS: The mean pretreatment potassium for the cohort was 6.57±0.52 mmol/L. After insulin-glucose treatment, mean potassium lowering was 0.84±0.58 mmol/L in patients with cirrhosis compared with 1.33±0.75 mmol/L for controls (p<0.001). The proportion of patients achieving normokalaemia was 33% for patients with cirrhosis, compared with 53% for controls (p=0.001). By multivariable regression, on average, liver cirrhosis was associated with a reduced potassium lowering effect of 0.42 mmol/L (95% CI 0.22 to 0.63 mmol/L, p<0.001) from insulin-glucose treatment, after adjusting for age, serum creatinine, cancer, pretreatment potassium level, ß-blocker use and cotreatments (sodium polystyrene sulfonate, salbutamol, sodium bicarbonate). CONCLUSIONS: Our observational data suggest reduced efficacy of insulin-glucose treatment for hyperkalaemia in patients with cirrhosis.

Observational study of the incidence and factors associated with patient readmission from home-based care under the Hospital in the Home programme.

BACKGROUND: Hospital in the Home (HITH) provides home-based care by hospital staff, which reduces inpatient length of stay and promotes a better quality of life. The frequency and precipitants for readmission from HITH back to the acute inpatient service are currently poorly defined. AIMS: To determine the incidence of hospital readmissions and risk factors for readmissions in a HITH programme of a large hospital network. METHODS: We conducted a retrospective cohort study of adult patients admitted to a large HITH service within a hospital network in Victoria, Australia, from 1 July to 30 September 2017. We used logistic regression to determine if patient characteristics or specific clinical factors were associated with hospital readmission. RESULTS: In a cohort of 605 patients under HITH, 72 were readmitted (incidence 11.9%). The median duration under HITH prior to readmission was 7 days (interquartile range, 3-23 days). Most readmissions were due to treatment failure, an associated complication or new clinical problem. In the univariable analysis, older age, direct admission from the emergency department (ED), recent intensive care admission, high Charlson comorbidity index, advanced chronic kidney disease, negative pressure wound therapy and use of antihypertensives were factors associated with readmission. In the multivariable analysis, the variables independently associated with readmissions were the Charlson comorbidity index (odds ratio, OR 1.17, 95% CI: 1.08-1.25) and referrals from the ED (OR 0.18, 95% CI: 0.06-0.58). CONCLUSIONS: Older age and greater comorbidity increased the odds of readmission, but patients from the ED were low risk compared to inpatient referrals.